Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer.
Future Oncol
; 17(3): 291-299, 2021 Jan.
Article
en En
| MEDLINE
| ID: mdl-32996811
ABSTRACT
Aim:
Study first-line (1L) treatment patterns and economic outcomes among patients with advanced metastatic gastric cancer (GC) and esophageal cancer (EC). Materials &methods:
Newly diagnosed patients with systemic GC and EC treatments were identified between 1 January 2011 and 31 July 2017; costs were presented as per patient per month (PPPM) basis.Results:
Study included 392 GC and 436 EC patients. Most frequently used 1L regimens were 5-fluorouracil (5-FU) + oxaliplatin (22.5%) and epirubicin + cisplatin + 5-FU (ECF)/ECF modifications (21.9%) in patients with GC; and carboplatin + paclitaxel (29.6%) and 5-FU + oxaliplatin (11.5%) in EC patients. Mean all-cause costs were US$16,242 PPPM for GC, and $18,384 PPPM for EC during 1L treatment.Conclusion:
GC and EC were resource intensive and costly. High costs and short treatment durations underscored a gap in care in 1L treatment.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Neoplasias Gástricas
/
Neoplasias Esofágicas
/
Aceptación de la Atención de Salud
/
Costos de la Atención en Salud
Tipo de estudio:
Health_economic_evaluation
/
Observational_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Future Oncol
Año:
2021
Tipo del documento:
Article
País de afiliación:
Estados Unidos